Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.4 |
mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.037 | 0.4 |
mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.4 |